NDA 018321 · Curium
Technescan Hdp
Technetium Tc-99m Oxidronate Kit · Injection
Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Feb 18, 1981
Approved uses
2
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
136
68 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 5, 2025.
INDICATIONS AND USAGE Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in adult and pediatric patients.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 28, 1989 Supplement 8 · Efficacy
- Feb 18, 1981 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- TECHNESCAN HDP · TECHNETIUM TC-99M OXIDRONATE KIT N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Oxidronate Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea16
- bone scan abnormal14
- injection site pain10
- drug ineffective9
- headache9
- injection site swelling8
- injection site erythema7
- injection site extravasation7
- dizziness6
- product administration error6
- product preparation issue6
- radioisotope scan abnormal6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 11 |
| 2019 | 7 |
| 2020 | 11 |
| 2021 | 66 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Curium
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.